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Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal
doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with partially
platinum-sensitive relapse [6–12 months platinum-free interval (PFI)] is unclear.
Patients and methods: Within OVA-301, we therefore now report on the outcomes for the 214 cases in this
subgroup.
Results: Trabectedin/PLD resulted in a 35% risk reduction of disease progression (DP) or death [hazard ratio (HR) =
0.65, 95% conﬁdence interval (CI), 0.45–0.92; P = 0.0152; median progression-free survival (PFS) 7.4 versus 5.5
months], and a signiﬁcant 41% decrease in the risk of death (HR = 0.59; 95% CI, 0.43–0.82; P = 0.0015; median
survival 23.0 versus 17.1 months). The safety of trabectedin/PLD in this subset mimicked that of the overall population.
Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), although patients in the
trabectedin/PLD arm had a slightly lower proportion of further platinum (49% versus 55%). Importantly, patients in the
trabectedin/PLD arm survived signiﬁcantly longer after subsequent platinum (HR = 0.63; P = 0.0357; median 13.3
versus 9.8 months).
Conclusion: This hypothesis-generating analysis demonstrates that superior beneﬁts with trabectedin/PLD in terms
of PFS and survival in the overall population appear particularly enhanced in patients with partially sensitive disease
(PFI 6–12 months).
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introduction
Trabectedin is a marine-derived antineoplastic agent, initially
isolated from the tunicate Ecteinascidia turbinata and currently
produced synthetically. It was ﬁrst approved as a single agent in
the European Union in 2007 and, subsequently, in many other
countries worldwide for patients with soft tissue sarcoma after
failure of standard-of-care chemotherapies. Trabectedin
showed encouraging single-agent activity in several phase II
trials in relapsed ovarian cancer [1–3]. Trabectedin plus
doxorubicin showed synergy in vitro [4, 5] and, in a phase I
trial, trabectedin plus pegylated liposomal doxorubicin (PLD,
CentoCor Ortho Biotech Products L.P., Raritan, NJ) was well
tolerated and provided clinical beneﬁt at therapeutic doses of
both drugs in pretreated patients with diverse tumor types
including ovarian cancer [6]. A randomized, multicenter, phase
III trial (OVA-301) evaluated the combination of trabectedin
plus PLD versus PLD alone in relapsed ovarian cancer, with
progression-free survival (PFS) by independent radiology
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PLD, trabectedin improved PFS over PLD alone, with a 21%
risk reduction of disease progression (DP) or death [hazard
ratio (HR) = 0.79; 95% conﬁdence interval (CI), 0.65–0.96; P =
0.0190; median 7.3 versus 5.8 months) and adequate
tolerability. In the platinum-sensitive stratum [platinum-free
interval (PFI) ‡ 6 months], the risk reduction of DP or death
was 27% (HR = 0.73; 95% CI, 0.56–0.95; P = 0.0170; median
PFS 9.2 versus 7.5 months). A protocol-speciﬁed interim
analysis of overall survival (OS) was conducted with 300 events
(versus 520 required for the ﬁnal OS analysis) showing a 15%
reduction in the risk of death with the combination (HR = 0.85;
P = 0.1506). Based mainly on these results, the European Union
Commission granted marketing authorization for trabectedin
combined with PLD for the treatment of patients with relapsed,
platinum-sensitive ovarian cancer in October 2009 [9].
The effectiveness of platinum re-treatment in relapsed ovarian
cancer is highly correlated with the PFI. A PFI ‡ 6 months
predicts platinum sensitivity, but within this group, a PFI of
6–12 months is considered to indicate a ‘partially’ platinum-
sensitive disease [10]. Platinum-based therapy is generally
accepted as standard in patients with PFI > 12 months, with
response rates ranging from 30% to 60%. Less consensus exists
as to the beneﬁts of platinum rechallenge in the partially
platinum-sensitive subgroup, where response rates to further
platinum are in the 25%–30% range [11]. Preclinical and
clinical data [12–15] indicate that, in relapsed ovarian cancer,
the artiﬁcial expansion of PFI with an intervening nonplatinum
therapy may be beneﬁcial possibly by reversing platinum
resistance, which may be of particular interest to patients with
partially platinum-sensitive disease (PFI 6–12 months).
Furthermore, clinically signiﬁcant toxicities such as
hypersensitivity reactions and residual neurotoxicity are
common and may hamper re-administration of platinum-
based chemotherapy, underscoring the need for an efﬁcacious
nonplatinum regimen [16, 17], particularly in the partially
platinum-sensitive population [10, 18]. Few phase III studies of
combination regimens versus platinum monotherapy or
comparing various nonplatinum single agents have reported
clinical outcomes in partially platinum-sensitive patients [19].
OVA-301 [7, 8] has been one of the largest conducted
randomized trials in relapsed ovarian cancer after failure of
platinum-based chemotherapy. One-third of the 672 randomized
patients in OVA-301 (n = 214, 32%) had a PFI from 6 to 12
months. The current post hoc, exploratory, hypothesis-generating
analysis provides a detailed assessment of results for the partially
platinum-sensitive population, including a description of
subsequent therapies administered to these patients.
patients and methods
study design
Full details of OVA-301 trial have been reported elsewhere [8]. Brieﬂy,
OVA-301 was an open-label, multicenter, randomized, phase III clinical
trial designed to investigate the efﬁcacy and safety of the combination of
PLD 30 mg/m
2 followed by trabectedin 1.1 mg/m
2 every 3 weeks compared
with PLD 50 mg/m
2 every 4 weeks. Eligible patients were women ‡18 years
old with histologically proven epithelial ovarian, fallopian tube, or primary
peritoneal carcinoma in relapse or progression after one platinum-based
chemotherapy regimen. Patients with platinum-resistant (PFI <6 months)
or platinum-sensitive disease (PFI ‡ 6 months) were eligible. The trial was
stratiﬁed based on platinum sensitivity (platinum resistant versus platinum
sensitive) and Eastern Cooperative Oncology Group performance status
(0–1 versus 2). The primary end point was PFS by independent radiology
assessment. Secondary analyses of PFS were based on independent
oncologist and investigator’s assessments. The trial was also powered for
OS. From April 2005 until May 2007, a total of 672 patients were
randomized: 335 (PLD) and 337 (trabectedin/PLD). The ﬁnal PFS analysis
was conducted with 389 PFS events assessed by independent radiology in
patients with radiologically measurable disease with a predetermined data
cut-off (15 May 2008) [8]. This report focuses on the outcomes in the
partially platinum-sensitive patients subset (PFI 6–12 months), with
updated OS data generated at the request of the regulatory authorities with
one additional year of follow-up (data cut-off, 31 May 2009) [9]. A
summarized description of subsequent therapies is provided.
statistical methods
Efﬁcacy analysis populations include all randomized (intent-to-treat) and
all measurable (all randomized patients with radiologically measurable
disease) patients. The primary analysis of PFS was conducted in the ‘all
measurable’ dataset by independent radiology review. Unless otherwise
speciﬁed, all other efﬁcacy analyses were performed on the all randomized
analysis set. PFS and OS were estimated using the Kaplan–Meier method
and arms were compared by the log-rank test. A Cox proportional hazards
model was used to compare treatment arms after adjusting by baseline
prognostic factors.
results
The most representative baseline characteristics for the partially
platinum-sensitive subset of patients (n = 214) are given in
Table 1. They did not differ from those in the overall study
population [8].
progression-free survival
Results of the primary end point (PFS by independent
radiology review) in the partially platinum-sensitive subset of
patients are shown in Figure 1. The HR was 0.65 (95% CI,
0.45–0.92), indicating a 35% risk reduction of DP or death
signiﬁcantly favoring the trabectedin/PLD combination
(P = 0.0152). Median PFS was 7.4 months in the trabectedin/
PLD arm versus 5.5 months in the PLD arm. When compared
with PFS results for other subsets of patients according to PFI
(Table 2), the largest beneﬁt with trabectedin/PLD treatment
was obtained in the partially platinum-sensitive subset.
The secondary, supportive analysis of PFS by independent
oncology review showed an HR of 0.54 (95% CI, 0.39–0.76), i.e.
a statistically signiﬁcant 46% risk reduction of DP or death
(P = 0.0002) with the trabectedin/PLD combination (Table 2).
overall survival
At the 31 May 2009 cut-off, a total of 419 of the 672
randomized overall population had died (n = 215, PLD; n =
204, trabectedin/PLD), which represents 81% of the 520 death
events required for the ﬁnal OS analysis per protocol. In this
updated analysis, trabectedin/PLD combination resulted in
a 15% decrease in the risk of death compared with PLD alone
(HR = 0.85, 95% CI, 0.70–1.03; P = 0.092). Median OS was
22.4 months (95% CI, 19.4–25.1) in the trabectedin/PLD arm
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(Figure 2A).
In the partially platinum-sensitive subset of patients,
trabectedin/PLD induced a signiﬁcant 41% decrease in the risk of
death compared with PLD alone (HR = 0.59; 95% CI, 0.43–0.82;
P = 0.0015). Median OS was 23.0 months in the trabectedin/PLD
arm versus 17.1 months in the PLD arm (Figure 2B).
A multivariate analysis in the overall population showed
a signiﬁcantly longer survival with trabectedin/PLD after
covariate adjustment for prognostic factors, with an 18% risk
reduction of death (HR = 0.82; 95% CI, 0.67–0.99; P = 0.041;
Table 3). In this multivariate analysis, one of the most relevant
prognostic factors was PFI (P < 0.0001). Because PFI was
signiﬁcantly unbalanced favoring the PLD arm (mean PFI 13.3
months in PLD arm versus 10.6 months in the trabectedin/PLD
arm; P = 0.009), a Cox proportional hazards model was used to
compare OS in the two arms adjusting by PFI. This analysis
showed a statistically signiﬁcant 24% risk reduction of death
(HR = 0.76, 95% CI, 0.62–0.92; P = 0.0046) for patients
randomized to the trabectedin combination (Figure 3).
subsequent therapy
In OVA-301 study, similar proportions of patients received
subsequent therapy in each treatment arm (77% versus 76%;
P = 0.8195). The proportion of further platinum-based
therapies in the trabectedin/PLD arm was slightly lower than in
the PLD arm: 49% versus 55%, P = 0.1236 (56% versus 57%,
p=0.8900 in the PFI 6-12 subset).
In the subset of patients with partially platinum-sensitive
disease, time from randomization to subsequent platinum was
signiﬁcantly longer (HR = 0.64; P = 0.0167; median 9.8 versus
7.9 months) for patients in the trabectedin/PLD combination
arm (Figure 4). Furthermore, patients randomly assigned to the
trabectedin/PLD combination experienced signiﬁcantly longer
survival counted from the initiation of subsequent platinum-
based therapy: HR = 0.63; 95% CI, 0.41–0.97; P = 0.0357;
median 13.3 months in the trabectedin + PLD arm versus 9.8
months in the PLD arm (Figure 5). A detailed description of
subsequent therapies in this trial is reported separately [20].
Table 1. Baseline characteristics of the partially platinum-sensitive
subset of patients (OVA-301 study)
Arm P value
a
PLD Trabectedin/PLD
No. of patients 91 123
Age, years
Median 56 57 0.9635
Range 37–82 40–76
Race (%)
White 84 83 1.0000
Other 16 17
ECOG PS (%)
0 65 70 0.4617
>03 5 3 0
Platinum-free interval, months
Median
b 8.3 7.9 0.2186
Histology (%)
Papillary/serous 71 70 0.8798
Other 29 29
Prior lung/liver metastases (%) 35 42 0.3956
Prior taxane (%) 81 76 0.4061
Patient characteristics were well balanced and not different from those of
the overall population.
aRange was 6–12 months.
bFisher exact test for categorical variables and Wilcoxon–Mann–Whitney
for continuous variables.
ECOG, Eastern Cooperative Oncology Group; PLD, pegylated liposomal
doxorubicin; PS, performance status.
Figure 1. Progression-free survival for the partially platinum-sensitive population (OVA-301 study). independent radiology review of all measurable
patients (primary end point). HR, hazard ratio; N, number of patients; P, log-rank test P value; PLD, pegylated liposomal doxorubicin.
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Volume 22|No. 1|January 2011 doi:10.1093/annonc/mdq352 | 41Table 2. Progression-free survival results according to platinum-free interval: independent radiology review (primary analysis) and independent oncology review (secondary analysis) (OVA-301 study)
Assessment PFI (months Median PFS (months) HR (trabectedin/PLD versus
PLD) and 95% CI (log scale)
HR (95% CI) PFS events/number P value
a
PLD Trabectedin/
PLD
PLD Trabectedin/
PLD
Independent radiology review 0–6 3.7 4.7 0.94 (0.68–1.29) 78/109 74/109 0.6793
6–12 5.5 7.4 0.65 (0.45–0.92) 55/86 69/122 0.0152
>12 8.9 11.1 0.70 (0.47–1.03) 57/117 48/93 0.0707
Independent oncology review 0–6 3.7 3.7 0.94 (0.69–1.26) 90/117 82/115 0.6631
6–12 3.8 8.4 0.54 (0.39–0.76) 68/91 73/123 0.0002
>12 9.0 11.1 0.66 (0.46–0.97) 63/122 49/94 0.0311
Data for partially platinum-sensitive patients are given in shaded rows.
aLog-rank test.
CI, conﬁdence interval; HR, hazard ratio; PFI, progression-free interval; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin.
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1drug exposure and safety
Exposure to treatment in the PFI 6–12 months patient subset
was similar to that in the overall patient population [8]. The
median number of cycles received was 5 (range, 1–21) in the
PLD arm and 6 (range, 1–15) in the trabectedin/PLD arm; 24%
and 40% of patients received seven or more cycles. The safety
proﬁle was not different from that in the overall population
(Table 4). Notably, when compared with single-agent PLD, the
trabectedin/PLD combination induced a higher incidence of
transient neutropenia and transaminase elevations and a lower
incidence of symptomatic events, namely hand and foot
syndrome and mucositis. Exposure to previous taxanes did not
result in a different liver function test pattern. Unlike
established platinum and taxane-based regimens, trabectedin/
PLD was associated with greatly diminished incidence of
neuropathy and alopecia, as well as lack of end organ,
cumulative toxic effects. The addition of trabectedin to PLD
did not result in a decrement in overall health status, as assessed
by patient reported outcomes.
discussion
OVA-301 was a large (n = 672), rigorously conducted
randomized trial evaluating the combination of trabectedin
plus PLD versus PLD alone in patients with relapsed ovarian
cancer. The trial met its primary end point, demonstrating
signiﬁcantly superior PFS with the combination conﬁrmed by
both independent radiology and independent oncology reviews,
Figure 2. Updated interim analysis of overall survival for OVA-301 study (cut-off, 31 May 2009). (A) All randomized patients. (B) Partially platinum-
sensitive population. HR, hazard ratio; N, number of patients; P, log-rank test P value; PLD, pegylated liposomal doxorubicin.
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Beneﬁts appeared more evident in the platinum-sensitive
stratum (PFI ‡ 6 months), where the risk reduction of DP or
death was 27% (HR = 0.73; 95% CI, 0.56–0.95; P = 0.0170;
median PFS 9.2 versus 7.5 months) [8].
updated survival analysis in the overall population
The updated interim analysis of survival, with 419 death
events (38% censored data) and an additional year of follow-
up, continues to show a favorable trend for trabectedin/PLD
arm, with an identical 15% reduction in the risk of death than
that shown 1 year earlier [8]. Nevertheless, with a larger
number of death events (419 versus 300) in this more mature
dataset, a more evident separation of the survival curves is
shown, the 95% CI around the HR is narrower, and the P
value is now 0.092 (versus 0.151 previously; Figure 2A).
Median OS was almost identical at 19.5 months in the PLD
arm but is now improved to 22.4 months in the trabectedin/
P L Da r m ,i . e .an e a r l y3 - m o n t hp r o l o n g a t i o ni nm e d i a n
survival for patients randomly assigned to the combination
arm. Therefore, the updated interim survival results conﬁrm
and strengthen those reported previously in a more mature
dataset with 1 year longer follow-up.
A relevant ﬁnding emerged when OS data for the overall
population was adjusted for the existing PFI imbalance between
treatment arms. When corrected by such imbalance, the Cox
proportional hazards model showed a statistically signiﬁcant
24% risk reduction for death (P = 0.0046) in patients randomly
assigned to the trabectedin/PLD regimen in the updated dataset
for the overall population. Pending the ﬁnal OS analysis to be
conducted once the required 520 events are reached, the
current data suggest that trabectedin in combination with PLD
may prolong survival over PLD alone in the overall population
of patients with relapsed ovarian cancer.
outcomes with trabectedin/PLD in patients with
partially platinum-sensitive disease
Patients whose ovarian cancer responds to ﬁrst-line platinum-
based therapy and relapse between 6 and 12 months after
completion of this initial chemotherapy represent
a subpopulation with a dismal outcome (1-year median survival)
[21] for whom there is a high need for new effective treatment
options, including nonplatinum alternatives. Single-agent PLD is
Table 3. Multivariate analysis of overall survival for prognostic factors
(OVA-301 study; overall population; updated analysis, cut-off, 31 May 2009)
Variable Hazard ratio 95% hazard
ratio conﬁdence
limits
P value
Treatment group 0.816 0.672 0.991 0.0407
Prior taxane 1.355 1.045 1.757 0.0217
ECOG PS 1.562 1.275 1.914 <0.0001
Race 1.159 0.920 1.461 0.2112
PFI 0.946 0.932 0.959 <0.0001
CA 125 1.191 0.915 1.551 0.1934
Age (years) 1.006 0.996 1.016 0.2329
Liver/lung metastases 1.412 1.160 1.719 0.0006
Ascites at baseline 2.124 1.737 2.596 <0.0001
Bulky disease 1.601 1.310 1.956 <0.0001
Groups for analysis: treatment arm (PLD versus trabectedin + PLD); prior
taxane (no versus yes); ECOG PS (0 versus >0); race (white versus others);
PFI and age (continuous variables); CA 125 (<2x ULN versus ‡2x ULN);
liver/lung metastases (no versus yes); ascites (no versus yes); bulky disease
(no versus yes).
ECOG, Eastern Cooperative Oncology Group; PFI, platinum-free interval;
PLD, pegylated liposomal doxorubicin; PS, performance status; ULN,
upper limit of normal.
Figure 3. Overall survival adjusted by continuous platinum-free interval (OVA-301 study, cut-off, 31 May 2009). HR, hazard ratio; P, Cox regression P
value; PLD, pegylated liposomal doxorubicin.
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Institute for Clinical Excellence (http://www.nice.org.uk) and the
National Comprehensive Cancer Network guidelines (http://
www.nccn.org). As expected, previous results of a multivariate
analysis in OVA-301 showed PFI as an independent predictor of
outcomes for both PFS and OS [8]. The data in the hypothesis-
generating analyses reported here show that beneﬁts with
trabectedin/PLD combination appeared more pronounced in
patients with partially platinum-sensitive disease, with a 35%–
46% risk reduction of DP or death versus PLD alone by
independent radiology and independent oncology review,
respectively, compared with the corresponding 21%–28% ﬁgures
in the overall population [8].
Notably, a 41% reduction in the risk of death was obtained
for the subset of patients with partially platinum-sensitive
disease randomized to the trabectedin combination (P =
0.0015), with median OS extended by 6 months versus PLD
alone. Therefore, the survival beneﬁts with the trabectedin/PLD
regimen appeared markedly enhanced in patients with partially
platinum-sensitive disease.
The positive trend toward a survival advantage with the
trabectedin/PLD combination versus PLD alone observed in
Figure 4. Time from randomization to subsequent platinum-based therapy in the partially platinum-sensitive subpopulation (OVA-301 study, PFI 6- to
12-month subset, n = 121). HR, hazard ratio; N, number of patients; P, log-rank test P value; PLD, pegylated liposomal doxorubicin.
Figure 5. Overall survival from subsequent platinum-based therapy in the partially platinum-sensitive population (OVA-301 study, PFI 6- to 12-month
subset; n = 121). Censored: PLD arm (21%); trabectedin/PLD arm (42%). HR, hazard ratio; N, number of patients; P, log-rank test P value; PLD, pegylated
liposomal doxorubicin.
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PFI 6- to 12-month subset, appears unlikely due to the effects
of subsequent therapies received by the patients after
discontinuing study medication in this trial. Roughly the same
proportion of patients in each arm received subsequent
therapy, and the patients treated with trabectedin/PLD received
a slightly lower proportion of further platinum-based therapies
compared with those treated with PLD alone.
The administration of subsequent platinum was signiﬁcantly
delayed for patients in the trabectedin/PLD combination. Such
PFI extension may represent an added beneﬁt for these
patients, at the very least by allowing extra time to recover
from toxic effects of their front-line platinum-based therapy.
Furthermore, patients randomly assigned to the trabectedin/
PLD combination experienced signiﬁcantly longer survival
counted from the initiation of subsequent platinum. The
current hypothesis-generating analyses suggest that the
enhanced survival beneﬁts with trabectedin/PLD over single-
agent PLD in OVA-301, particularly in patients with partially
platinum-sensitive disease, may be due to an extension of the
PFI. This hypothesis should be conﬁrmed in prospective
randomized trials.
No new or unexpected safety ﬁndings were seen with
trabectedin/PLD combination in the PFI 6-12 subpopulation
relative to those observed for the overall population [8]; thus,
the toxic effects of this combined chemotherapy are predictable
and manageable. This is consistent with the lack of
pharmacokinetic interactions between these two drugs found in
previous studies with PLD [6] or nonliposomal doxorubicin
[22, 23]. Therefore, this safety proﬁle together with current PFS
and interim OS results provide evidence for a highly favorable
beneﬁt/risk outcome in the partially platinum-sensitive
subpopulation, in which there is a high unmet need for new
treatment options.
relevance of OVA-301 results within the context of
relapsed ovarian cancer
Results for the partially platinum-sensitive population in OVA-
301 are given in Table 5 in context with results of other phase
III randomized trials in relapsed, platinum-sensitive ovarian
cancer [24–26]. OVA-301 [8] included patients with platinum-
resistant disease (35% of patients), whereas the other trials
solely included patients with platinum-sensitive ovarian cancer.
The CALYPSO trial conducted by the GINECO group within
the Gynecologic Cancer Intergroup, compared carboplatin/
PLD versus carboplatin/paclitaxel, and reported separate results
for the partially platinum-sensitive population [27]. In this
subset, better PFS outcomes were also obtained with
carboplatin/PLD versus carboplatin/paclitaxel (27% risk
reduction of DP or death; median PFS 9.4 versus 8.8 months).
It is to be stressed that the PFS analyses in OVA-301 used a very
rigorous methodology and strict scrutiny. Data assessed by an
independent radiology panel blinded to treatment arm
assignment in patients with measurable disease were the basis
of the primary analysis. In addition, as a sensitivity analysis, an
independent oncology review, also blinded to treatment
allocation, combined the results of the radiology review with
clinical outcomes in evaluable disease.
OVA-301 conﬁrmed the superiority of trabectedin/PLD
combination compared with PLD alone in relapsed ovarian
cancer [7], and the current analysis strongly suggests that the
greatest beneﬁts in PFS and survival are obtained among
patients with partially platinum-sensitive disease. Since most
women with relapsed ovarian cancer will eventually experience
DP and will die of their disease, both safety and efﬁcacy are
important in assessing the role of a novel combination in this
disease setting. The use of a nonplatinum-based combination
may allow treatment for patients having not yet recovered from
Table 4. Main treatment-related adverse events reported in partially platinum-sensitive patients and in the overall population (OVA-301 study)
Partially platinum-sensitive patients (PFI 6–12 months) All patients
PLD (n = 91) Trabectedin/PLD (n = 123) PLD (n = 330) Trabectedin/PLD (n = 333)
Grade Grade Grade Grade
Any 3 4 Any 3 4 Any 3 4 Any 3 4
Hematological
Febrile neutropenia 2 1 1 5 3 2 2 2 <17 5 2
Neutropenia 72 23 9 92 34 39 74 20 10 92 30 42
Thrombocytopenia 30 2 – 68 8 9 27 2 2 64 12 11
Nonhematological
Alopecia 19 – – 15 – – 13 – – 12 – –
ALT increase 36 1 – 98 46 5 36 2 – 96 46 5
Fatigue 33 3 – 48 8 1 30 2 <14 2 6 <1
Mucosal inﬂammation 21 7 – 11 2 – 19 6 – 11 2 –
Nausea 39 4 – 74 11 – 38 2 – 71 9 –
Peripheral sensory
neuropathy
2––3–– 2 – – 4– –
PPD syndrome 47 17 – 29 5 – 54 18 1 24 4 –
Stomatitis 31 4 – 19 2 – 31 5 <11 9 1 –
Vomiting 27 2 – 47 8 1 24 2 – 52 10 <1
Data shown are % of patients. ALT, alanine aminotransferase; PPD, palmar-plantar erythrodysesthesia.
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hypersensitivity) [28, 29] and, as suggested in the partially
platinum-sensitive subpopulation of OVA-301, may provide
a further survival advantage after the reintroduction of
subsequent platinum. This might be due to a reversal of the
partial resistance pattern [15], a hypothesis that warrants
a prospective trial. Furthermore, as trabectedin has been
advocated as an interesting agent to utilize in patients with
carboplatin hypersensitivity as a ‘platinum substitute,’ this
raises some interesting questions related to biology and clinical
behavior, which require a randomized study (with surrogate
and translational endpoints) comparing both drugs in the same
population.
The trabectedin/PLD combination provides a new option for
platinum-sensitive patients with relapsed ovarian cancer
after failure of ﬁrst-line platinum-based chemotherapy.
Because re-treatment with platinum-based therapy remains
a viable option in this setting, further studies comparing
trabectedin/PLD with a platinum-containing combination are
warranted. Thus, a large randomized intergroup trial is currently
in late stages of preparation to evaluate OS in patients with
partially platinum-sensitive relapsed ovarian cancer treated
initially with trabectedin/PLD (and followed by platinum-
based therapy upon relapse) versus carboplatin/PLD, the
regimen recently evaluated in the CALYPSO trial [26, 27].
In conclusion, the randomized phase III trial OVA-301
demonstrates that trabectedin combined with PLD induced
enhanced beneﬁts in terms of PFS and survival, and thus
represents a safe and effective nonplatinum, nontaxane
alternative for the treatment of patients with relapsed
platinum-sensitive ovarian cancer. The results of the
hypothesis-generating analyses reported here in the important
subset of patients with partially sensitive disease (PFI 6–12
months) strongly suggest an enhanced beneﬁt of trabectedin/
PLD regimen in this subpopulation. Trabectedin in
combination with PLD may be administered to relapsed
ovarian cancer patients while they recover from prior
platinum-related toxic effects, and prolongation of PFI could
help to improve response to—and survival after–subsequent
platinum-based therapy.
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Table 5. Results of phase III randomized clinical trials evaluating combination regimens for second-line therapy of platinum-sensitive patients
Treatment Paclitaxel/carboplatin Gemcitabine/carboplatin PLD/carboplatin PLD/trabectedin
Control Carboplatin Carboplatin Carboplatin/paclitaxel PLD
Study Parmar et al. [24] Pﬁsterer et al. [25] Pujade-Lauraine et al. [26],
Vasey et al. [27]
Monk et al. [8]
Number of patients
a 392 178 466 337
b
Prior taxane (%) 40 71 100 80
% PFI 6–12 months
c 23
d 40 35 37
e
Efﬁcacy results in total population/patients with PFI 6–12 months
Primary end point OS PFS PFS PFS (independent
radiology review)
f
PFS (independent
oncology review)
g
PFS, median (months) 13.0/NA 8.6/NAi 11.3/9.4 7.3/7.4 7.4/8.4
Risk reduction of DP or
death versus control
Y24%/NA Y28%/NA Y18%/Y27% Y21%/Y35% Y28%/Y46%
OS, median (months) 29.0/NA 18/NA NA 22
h/23
Risk reduction of death
versus control
Y18%/NA Y4%/NA NA Y15%
h/Y41%
Added toxicity versus
control
Myelotoxicity, neurotoxicity Myelotoxicity Hand and foot
syndrome, mucositis
Myelotoxicity, LFTs
aFor randomized controlled trials, number of patients in the combination arm.
b337 patients was the overall population in trabectedin/PLD arm, of whom 218 had platinum-sensitive disease.
cPartially platinum-sensitive.
dPFI £ 12 months.
eOVA-301 included 35% of patients with platinum-resistant disease (PFI < 6 months).
fPrimary analysis.
gSecondary supportive analysis.
hCurrent updated survival analysis.
iEfﬁcacy (PFS) outcomes not based on independent review.
LFT, liver function tests; NA, not available; OS, overall survival; DP, disease progression; PFI, platinum-free interval; PFS, progression-free survival; PLD,
pegylated liposomal doxorubicin.
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